SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Amendment No. 2)
Under the Securities Exchange Act of 1934
Keryx Biopharmaceuticals, Inc.
------------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
---------------------------------------
(Title of Class of Securities)
492515101
(CUSIP Number)
--------------
Lindsay A. Rosenwald, M.D.
--------------------------
787 Seventh Avenue
------------------
New York, NY 10019
------------------
(212) 554-4300
--------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
May 22, 2006
------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Statement because of Rule
13d-1(b)(3) or (4), check the following:
Check the following box if a fee is being paid with this Statement:
------------------- -----------------
CUSIP No. 492515101 13D/A Page 2 of 5 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Lindsay A. Rosenwald, M.D.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) (b)
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO (see Item 3 below)
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e)
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF SHARES 2,165,823
BENEFICIALLY --------------------------------------
OWNED BY EACH 8 SHARED VOTING POWER
REPORTING PERSON 0
WITH --------------------------------------
9 SOLE DISPOSITIVE POWER
2,165,823
--------------------------------------
10 SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,165,823
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES*
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.0%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
--------------------------------------------------------------------------------
-2-
This Amendment No. 2 amends and supplements the following items of the Statement
on Schedule 13D filed by Lindsay A. Rosenwald (the "Reporting Person") on May
29, 2003, as amended by Amendment No. 1 filed December 3, 2004 (the "Schedule").
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended as follows:
On May 22, 2006, the Reporting Person transferred 1,000,000 shares of Common
Stock of the company, par value $.001 per share (the "Shares"), to The Lindsay A
Rosenwald 2000 (Delaware) Irrevocable Indenture of Trust dated May 24, 2000 (the
"Trust"). The Reporting Person disclaims beneficial ownership of securities
owned by the Trust.
Item 5. Interest in Securities of Issuer.
Item 5(a) is hereby amended as follows:
(a) As of the date hereof, the Reporting Person may be deemed to
beneficially own 2,165,823 Shares comprised of (i) 1,735,863
Shares directly owned by the Reporting Person; (ii) 320,786
Shares owned by Paramount BioCapital Investments, LLC of which
the Reporting Person is managing member, (iii) 45,000 Shares
issuable to the Reporting Person upon exercise of options to
purchase Shares that have vested or will vest within sixty (60)
days; (iv) 14,064 Shares issuable to Reporting Person upon
exercise of warrants to purchase Shares; and (v) 50,110 Shares
issuable to Paramount BioCapital Investments, LLC, of which the
Reporting Person is managing member, upon exercise of warrants to
purchase Shares. Such Shares constitute approximately 5.0% of the
Issuer's outstanding shares of Common Stock, based upon
43,112,221 Shares outstanding as of May 4, 2006.
Item 5(c) is hereby amended as follows:
(c) Item 3 is incorporated herein by reference.
Item 6. Contracts, Arrangements, Understandings or Relationships with respect
to Securities of the Issuer
Item 6 is hereby amended as follows:
(a) The Reporting Person is a member of the Issuer's board of
directors.
-3-
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: May 22, 2006
New York, NY By /s/ Lindsay A. Rosenwald, M.D.
-----------------------------
Lindsay A. Rosenwald, M.D.
-4-